WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 51 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances O [ ff. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in Cumulative List No. 10, 2002 (available in CD- ROM only).
Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 51 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45) dans la Liste récapitulative No. 10, 2002 (disponible sur CD-ROM seulement) .
Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) Denominaciones Comunes Internacionales RECOMENDADAS: Lista 51 De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales R ecomendadas para las Sustancias Farmacéuticas [ Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–85) y Recomendadas (1–45) se encuentran reunidas en Cumulative List No. 10, 2002 (disponible sólo en CD-ROM) .
83
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
Latin , English, French, Spanish: Recommended INN DCI Recommandée DCI Recomendada
Chemical name or description; Molecular formula; Graphic formula Nom chimique ou description; Formule brute; Formule développée Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada
adargileukinum alfa adargileukin alfa adargileukine alfa adargileukina alfa
[88-arginine]interleukin 2 (human clone pTIL2-21a) (partly glycosylated) [88-arginine]interleukine 2 humaine (clone pTIL2-21a) (en partie glycosylée) [88-arginina]interleukina 2 humana (clon pTIL2-21a) (parcialmente glicosilada) C695H1124N180O202S7 (peptide)
APTSSSTKKT TFKFYMPKKA RPRDLISRIN WITFCQSIIS
QLQLEHLLLD TELKHLQCLE VIVLELKGSE TLT
LQMILNGINN EELKPLEEVL TTFMCEYADE
YKNPKLTRML NLAQSKNFHL TATIVEFLNR
alamifovirum alamifovir alamifovir alamifovir
bis(2,2,2-trifluoroethyl) [(2-{2-amino-6-[(4-methoxyphenyl)sulfanyl]9H-purin-9-yl}ethoxy)methyl]phosphonate [[2-[2-amino-6-[(4-méthoxyphényl)sulfanyl]-9H-purin9-yl]éthoxy]méthyl]phosphonate de bis(2,2,2-trifluoroéthyle) [(2-{2-amino-6-[(4-metoxifenil)sulfanil]-9H-purin9-il}etoxi)metil]fosfonato de bis(2,2,2-trifluoroetilo) C19H20F6N5O5 PS H3CO S N H2N N N N O O P O O CF 3 CF 3
84
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
aprinocarsenum aprinocarsen
2'-deoxy- P-thioguanylyl-(3'→5')- P-thiothymidylyl-(3'→5')P-thiothymidylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')P-thiothymidylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')-2'- deoxyP-thioguanylyl-(3'→5')-2'- deoxy- P-thiocytidylyl-(3'→5')P-thiothymidylyl-(3'→5')-2'-deoxy- P-thioguanylyl-(3'→5')-2'- deoxyP-thioguanylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-deoxyP-thioguanylyl-(3'→5')-2'- deoxy- P-thioadenylyl-(3'→5')-2'-deoxyP-thioguanylyl-(3'→5')- P-thiothymidylyl-(3'→5')- P-thiothymidylyl(3'→5')- P-thiothymidylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')2'-deoxyadenosine 2'-désoxy- P-thioadénylyl- (5'→3')-2'- désoxy- P-thiocytidylyl-(5'→3')P-thiothymidylyl-(5'→3')- P-thiothymidylyl-(5'→3')- P-thiothymidylyl(5'→3')-2'-désoxy- P-thioguanylyl-(5'→3')-2'- désoxy- P-thioadénylyl(5'→3')-2'-désoxy- P-thioguanylyl-(5'→3')- P-thiothymidylyl-(5'→3')2'-désoxy- P-thioguanylyl- (5'→3')-2'- désoxy- P-thioguanylyl-(5'→3')P-thiothymidylyl-(5'→3')-2'-désoxy- P-thiocytidylyl-(5'→3')-2'-désoxyP-thioguanylyl-(5'→3')-2'- désoxy- P-thiocytidylyl-(5'→3')P-thiothymidylyl-(5'→3')-2'-désoxy- P-thiocytidylyl-(5'→3')P-thiothymidylyl-(5'→3')- P-thiothymidylyl-(5'→3')-2'désoxyguanosine 2'-desoxi- P-tioadenilil-(5'→3')-2'- desoxi- P-tiocitidilil-(5'→3')P-tiotimidilil-(5'→3')- P-tiotimidilil-(5'→3')- P-tiotimidilil-(5'→3')2'-desoxi- P-tioguanilil-(5'→3')-2'- desoxi- P-tioadenilil-(5'→3')2'-desoxi- P-tioguanilil-(5'→3')- P-tiotimidilil-(5'→3')-2'-desoxiP-tioguanilil-(5'→3')-2'- desoxi- P-tioguanilil-(5'→3')- P-tiotimidilil(5'→3')-2'-desoxi- P-tiocitidilil-(5'→3')-2'-desoxi- P-tioguanilil-(5'→3')2'-desoxi- P-tiocitidilil-(5'→3')- P-tiotimidilil-(5'→3')-2'- desoxiP-tiocitidilil-(5'→3')- P-tiotimidilil-(5'→3')- P-tiotimidilil-(5'→3')2'-desoxiguanosina C196H249N68O105P19S19
aprinocarsen
aprinocarseno
belimumabum belimumab
immunoglobulin G1, anti-(human cytokine BAFF) (human monoclonal LymphoStat-B heavy chain), disulfide with human monoclonal LymphoStat-B λ-chain, dimer immunoglobuline G1, anti-(cytokine BAFF humaine) ; dimère du disulfure entre la chaîne lourde et la chaîne λ de l'anticorps monoclonal humain LymphoStat-B immunoglobulina G1, anti-(citoquina BAFF humana) ; dímero del disulfuro entre la cadena pesada y la cadena λ del anticuerpo monoclonal humano LymphoStat-B
bélimumab
belimumab
85
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
cantuzumabum mertansinum cantuzumab mertansine
immunoglobulin G1, anti-(mucin CanAg) (human-mouse monoclonal C242 heavy chain), disulfide with human-mouse monoclonal C242 light chain, dimer, conjugate at the 6-amino groups of four lysine residues forming an amide bond with (4RS)4-[(3-{[(1S)-2-{[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5 ]hexacosa10,12,14(26),16,18-pentaen-6-yl]oxy}-1-methyl-2-oxoethyl]= methylamino}-3-oxopropyl)disulfanyl]pentanoyl groups immunoglobuline G1, anti-(mucin CanAg) ; dimère du disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal de souris C242 humanisé dont les groupes 6-amino de quatre lysines sont amidifiés par l'acide (4RS)-4-[[3-[[(1S)2-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy12,20-diméthoxy-2,5,9,16-tétraméthyl-8,23-dioxo-4,24-dioxa9,22-diazatétracyclo[19.3.1.110,14.03,5]hexacosa10,12,14(26),16,18-pentaén-6-yl]oxy]-1-méthyl-2-oxoéthyl]= méthylamino]-3-oxopropyl]disulfanyl]pentanoïque inmunoglobulina G1, anti-(mucina CanAg) ; dímero del disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal humanizado de ratón C242 en el que los grupos 6-amino de cuatro lisinas están amidificados por ácido (4RS)4-[[3-[[(1S)-2-[[(1 S,2R,3S,5S,6S,16E,18E,20R,21S)-11-cloro21-hidroxi-2,5,9,16-tetrametil -12,20-dimetoxi-4,24-dioxa8,23-dioxo-9,22-diazatetraciclo[19.3.1.1 10,14.03,5 ]hexacosa10,12,14(26),16,18-pentaen-6-il]oxi]-1-metil-2-oxoetil]metilamino]3-oxopropil]disulfanil]pentanoico
cantuzumab mertansine
cantuzumab mertansina
O Ig N H S CH3 S H3C H3C H O O N H O
O
H CH3 N CH3 O H CH3 N Cl OCH3 O
H
H O OH
H OCH3
CH3
4
cantuzumab = Ig(NH2)4
cimicoxibum cimicoxib cimicoxib cimicoxib
4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol1-yl]benzenesulfonamide 4-[4-chloro-5-(3-fluoro-4-méthoxyphényl)-1H-imidazol1-yl]benzènesulfonamide 4-[4-cloro-5-(3-fluoro-4-metoxifenil)-1H-imidazol1-il]bencenosulfonamida
86
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
C16H13ClFN3O3S H 3CO F O O S NH 2 N N
Cl
dabuzalgronum dabuzalgron dabuzalgron dabuzalgrón
N-{6-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]2-methylphenyl}methanesulfonamide N-[6-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)méthoxy]2-méthylphényl]méthanesulfonamide N-{6-cloro-3-[(4,5-dihidro-1H-imidazol-2-il)metoxi]2-metilfenil}metanosulfonamida C12H16ClN3O3S H N CH3 O N N H
H3C
S O O Cl
dacinostatum dacinostat dacinostat dacinostat
(2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol3-yl)ethyl]amino}methyl)phenyl]propenamide (2E)-N-hydroxy-3-[4-[[(2-hydroxyéthyl)[2-(1H-indol3-yl)éthyl]amino]méthyl]phényl]prop-2-énamide (2E)-N-hidroxi-3-[4-({(2-hidroxietil)[2-(1H-indol3-il)etil]amino}metil)fenil]propenamida C22H25N3O3 HN N
H N O
OH
OH
87
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
dalbavancinum dalbavancin
5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O[2-deoxy-2-[(10-methylundecanoyl)amino]- ß- D -glucopyranuronosyl]38-[[3-(dimethylamino)propyl]carbamoyl]-42-O-a- D-mannopyranosyl15-Nmethyl(ristomycin A aglicone) (main component) acide 2-désoxy-1-O-[(3S,15R,18R,34R,35S,38S,48R,50aR)-5,31dichloro-38-[[3-(diméthylamino)propyl]carbamoyl]-6,11,34,40,44pentahydroxy-42-(a- D-mannopyranosyloxy)-15-(méthylamino)2,16,36,50,51,59-hexaoxo2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tétradécahydro20,23:30,33-diéthéno-3,18:35,48-bis(iminométhano)1H,15H-4,8:10,14:25,28:43,47-tétraméthéno34H-[1,14,6,22]dioxadiazacyclooctacosino[4,5-m][10,2,16]= benzoxadiazacyclotétracosén-56-yl]-2-[(10-méthylundécanoyl)= amino]-ß- D -glucopyranuronique (composant majeur) ácido 1-O -[(3S,15R,18R,34R,35S,38S,48R,50aR)-5,31-dicloro-38[[3-(dimetilamino)propil]carbamoil]-6,11,34,40,44-pentahidroxi-42(a- D-manopiranosiloxi)-15-(metilamino)-2,16,36,50,51,59-hexaoxo2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tetradecahidro20,23:30,33-dieteno-3,18:35,48-bis(iminometano) -1H,15H4,8:10,14:25,28:43,47-tetrameteno34H-[1,14,6,22]dioxadiazaciclooctacosino[4,5- m][10,2,16]= benzoxadiazaciclotetracosen-56-il]-2-[(10-metilundecanoil)amino]2-desoxi-ß-D -glucopiranurónico (componente principal) C88-H100-Cl2-N10-O28 HO O OH HO HO HO O HN HN H3C O HO H O Cl CO2H O OH HO HN O CH3 CH3 O O H H H N O H N H O Cl H H N O H N H O H H N O H N H O
dalbavancine
dalbavancina
OH HO O
OH
CH3
N CH3
88
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
deligoparinum natricum deligoparin sodium
sodium salt of depolymerised heparin obtained by a controlled chemical process based on generation of free radicals by means of metal ions and hydrogen peroxide. The heparin starting material is obtained from porcine intestinal mucosa. The process results in oligosaccharide fragments of heparin of varying lengths. The average relative molecular mass is about 3200 Daltons, ranging from 2250 to 3850 Daltons. The degree of sulfation is approximately 2.5 sulfate residues per disaccharide unit. sel de sodium d'héparine de basse masse moléculaire obtenue par par dépolymérisation à l'aide de radicaux libres (générés par des ions métalliques et du peroxyde d'hydrogène) d'héparine de muqueuse intestinale de porc. La majorité des composants présentent une structure acide 2-O-sulfo-α-D -glucopyranosuronique à l'extrémité non réductrice et une structure 2-désoxy-6- O-sulfo-2(sulfoamino)- D-glucopyranose à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative moyenne est voisine de 3200 (2250 à 3850) ; le degré de sulfatation est voisin de 2,5 par unité disaccharide. sal sódica de una heparina de baja masa molecular que se obtiene de la heparina de la mucosa intestinal porcina por despolimerización por radicales libres, generados por iones metálicos y peróxido de hidrógeno; la mayoría de los componentes tienen una estructura de ácido 2- O -sulfo- α-D -glucopiranosurónico en el extremo no-reductor de la cadena y una estructura 2-desoxy6- O- sulfo-2-(sulfoamino)-D -glucopiranosa en el reductor; la masa molecular media oscila entre 2250 y 3850, con un valor característico de unos 3200; el grado de sulfatación es alrededor de 2,5 por unidad de disacárido.
déligoparine sodique
deligoparina sódica
desvenlafaxinum desvenlafaxine dèsvenlafaxine desvenlafaxina
4-[(1RS)-2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol 4-[(1RS)-2-(diméthylamino)-1-(1-hydroxycyclohexyl)éthyl]phénol 4-[(1RS)-2-(dimetilamino)-1-(1-hidroxiciclohexil)etil]fenol C16H25NO2 OH H
CH3 N
and enantiomer et énanti omère CH 3 y enantiómero
HO
diboterminum alfa dibotermin alfa dibotermine alfa dibotermina alfa
human recombinant bone morphogenic protein-2 (hrBMP-2) protéine-2 humaine recombinante morphogénique de l'os (PMOrh2) proteína-2 humana recombinante morfogénica de hueso (PMOrh-2)
89
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
[C571H886 N160O 164 S9]2
QAKHKQRKRL FYCHGECPFP PTELSAISML
KSSCKRHPLY LADHLNSTNH YLDENEKVVL
VDFSDVGWND AIVQTLVNSV KNYQDMVVEG
WIVAPPGYHA NSKIPKACCV CGCR
diquafosolum diquafosol diquafosol dicuafosol
P1,P4-bis(5'-uridyl) tetrahydrogen tetraphosphate uridine(5')tétraphospho(5')uridine tetrahidrógenotetrafosfato de P1,P4-bis(5'-uridilo) C18H26N4O23 P4 HO O O P P O O O N H N
O
O O OH P O O HO H OH O P O N O HO O N
OH O
HO
OH
disermolidum disermolide
(3Z,5S,6S,7S,8R,9S,11Z,13S,14S,15S,16Z,18S)-8,14,18trihydroxy-19-[(2S,3R,4S,5R)-4-hydroxy-3,5-dimethyl6-oxotetrahydro-2H-pyran-2-yl]-5,7,9,11,13,15hexamethylnonadeca-1,3,11,16-tetraen-6-yl carbamate carbamate de (1S,2S,3R,4S,6Z,8S,9S,10S,11Z,13S)-3,9,13trihydroxy-14-[(2S,3R,4S,5R)-4-hydroxy-3,5-diméthyl6-oxotétrahydro-2H-pyran-2-yl]-2,4,6,8,10-pentaméthyl1-[(1S,2Z)-1-méthylpenta-2,4-diényl]tétradéca-6,11-diényle carbamato de (3Z,5S,6S,7S,8R,9S,11Z,13S,14S,15S,16Z,18S)8,14,18-trihidroxi-19-[(2S,3R,4S,5R)-4-hidroxi-3,5-dimetil6-oxotetrahidro-2H-piran-2-il]-5,7,9,11,13,15-hexametilnonadeca1,3,11,16-tetraen-6-ilo C33H55NO8 H2C H CH3 CH3 CH3 CH3 H H H H2N O O OH H H H3C OH H H OH CH3 H CH3 H
disermolide
disermolida
H O
OH H
O
H CH3
90
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
edifoligidum edifoligide
duplex of 2'-deoxy- P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')2'-deoxy- P-thioadenylyl-(3'→5')-2'-deoxy- P-thioguanylyl- (3'→5')2'-deoxy- P-thioadenylyl-(3'→5')- P-thiothymidylyl-(3'→5')P-thiothymidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'- deoxyP-thiocytidylyl-(3'→5')-2'- deoxy- P-thiocytidylyl-(3'→5')-2'-deoxyP-thiocytidylyl-(3'→5')-2'- deoxy- P-thioguanylyl-(3'→5')-2'-deoxyP-thiocytidylyl-(3'→5')-2'- deoxyguanosine and 2'- deoxyP-thioguanylyl-(3'→5')-2'- deoxy- P-thioadenylyl-(3'→5')P-thiothymidylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')-2'- deoxyP-thiocytidylyl-(3'→5')-2'- deoxy- P-thioguanylyl-(3'→5')-2'-deoxyP-thiocytidylyl-(3'→5')-2'- deoxy- P-thioguanylyl-(3'→5')-2'-deoxyP-thioguanylyl-(3'→5')-2'- deoxy- P-thioguanylyl-(3'→5')-2'-deoxyP-thioadenylyl-(3'→5')-2'- deoxy- P-thioadenylyl-(3'→5')-2'-deoxyP-thioadenylyl-(3'→5') -thymidine 2'-désoxy- P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-désoxyP-thioadénylyl-(3'→5')-2'- désoxy- P-thioguanylyl-(3'→5')-2'-désoxyP-thioadénylyl-(3'→5')- P-thiothymidylyl-(3'→5')- P-thiothymidylyl(3'→5')- P-thiothymidylyl-(3'→5')-2'-désoxy- P-thiocytidylyl-(3'→5')2'-désoxy- P-thiocytidylyl-(3'→5')-2'- désoxy- P-thiocytidylyl-(3'→5')2'-désoxy- P-thioguanylyl- (3'→5')-2'- désoxy- P-thiocytidylyl-(3'→5')2'-désoxyguanosine et P-thiothymidylyl-(5'→3')-2'- désoxyP-thioadénylyl-(5'→3')-2'- désoxy- P-thioadénylyl-(5'→3')-2'-désoxyP-thioadénylyl-(5'→3')-2'- désoxy- P-thioguanylyl-(5'→3')-2'-désoxyP-thioguanylyl-(5'→3')-2'- désoxy- P-thioguanylyl-(5'→3')-2'-désoxyP-thiocytidylyl-(5'→3')-2'- désoxy- P-thioguanylyl-(5'→3')-2'-désoxyP-thiocytidylyl-(5'→3')-2'- désoxy- P-thiocytidylyl-(5'→3')P-thiothymidylyl-(5'→3')-2'-désoxy- P-thioadénylyl-(5'→3')2'-désoxyguanosine partiellement complémentaires 2'-desoxi- P-tiocitidilil-(3'→5')- P-tiotimidilil-(3'→5')-2'- desoxiP-tioadenilil-(3'→5')-2'- desoxi- P-tioguanilil-(3'→5')-2'- deoxiP-tioadenilil-(3'→5')- P-tiotimidilil-(3'→5')- P-tiotimidilil-(3'→5')P-tiotimidilil-(3'→5')-2'- desoxi- P-tiocitidilil-(3'→5')-2'- desoxi- Ptiocitidilil-(3'→5')-2'-desoxi- P-tiocitidilil-(3'→5')-2'-desoxi- P-tioguanilil(3'→5')-2'-desoxi- P-tiocitidilil-(3'→5')-2'-desoxiguanosina y P-tiotimidilil-(5'→3')-2'- desoxi- P-tioadenilil-(5'→3')-2'-desoxiP-tioadenilil-(5'→3')-2'- desoxi- P-tioadenilil-(5'→3')-2'- desoxiP-tioguanilil-(5'→3')-2'- desoxi- P-tioguanill-(5'→3')-2'-disoxiP-tioguanilil-(5'→3')-2'- desoxi- P-tiocitidilil-(5'→3')-2'- desoxiP-tioguanilil-(5'→3')-2'- desoxi- P-tiocitidilil-(5'→3')-2'- desoxiP-tiocitidilil-(5'→3')- P-tiotimidilil-(5'→3')-2'- desoxi- P-tioadenilil(5'→3')-2'-desoxiguanosina parcialmente complementario (3'-5')d( P-thio) (C T A G A T T (5'-3')d(P-thio) (T
édifoligide
edifoligida
. . . T . C . C . C . G . C. G) . A A A G G G C G C C T A G)
91
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
edotecarinum edotecarin
12-ß-D -glucopyranosyl-2,10-dihydroxy-6-[[2-hydroxy1-(hydroxymethyl)ethyl]amino]-12,13-dihydro6H-indolo[2,3- a]pyrrolo[3,4-c ]carbazole-5,7-dione 12-ß-D -glucopyranosyl-2,10-dihydroxy-6-[[2-hydroxy1-(hydroxyméthyl)éthyl]amino]-12,13-dihydro6H-indolo[2,3- a]pyrrolo[3,4-c ]carbazole-5,7-dione 12-ß-D -glucopiranosil-2,10-dihidroxi-6-[[2-hidroxi1-(hidroximetil)etil]amino]-12,13-dihidro-6H-indolo[2,3- a]pirrolo= [3,4- c ]carbazol-5,7-diona C29 H2 8N4O1 1 HO O N HN HO O N OH HO OH OH O H N
édotécarine
edotecarina
OH OH
edratidum edratide
glycyl- L-tyrosyl- L-tyrosyl- L-tryptophyl- L-seryl- L-tryptophyl-L-isoleucylL-arginyl- L-glutaminyl- L-prolyl- L-prolylglycyl- L-lysylglycyl- L-glutamylL-glutamyl- L-tryptophyl- L-isoleucylglycine glycyl- L-tyrosyl- L-tyrosyl- L-tryptophyl- L-séryl- L-tryptophyl-L-isoleucylL-arginyl- L-glutaminyl- L-prolyl- L-prolyl-glycyl - L-lysyl-glycylL-glutamyl- L-glutamyl- L-tryptophyl-L-isoleucyl-glycine glicil- L-tirosil- L-tirosil- L-triptofil- L-seril- L-triptofil- L-isoleucil- L-arginilL-glutaminil- L-prolil- L-prolilglicil- L-lisilglicil- L-glutamil- L-glutamilL-triptofil- L-isoleucilglicina C111H149N27O28 H Gly Pro Tyr Gly Tyr Lys Trp Gly Ser Glu Trp Glu Ile Trp Arg Ile Gln Pro 10
édratide
edratida
Gly OH 19
92
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
elsilimomabum elsilimomab
immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 κ-chain, dimer immunoglobuline G1, anti-(interleukine 6 humaine) ; dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal de souris B-E8 inmunoglobulina G1, anti-(interleuquina 6 humana) ; dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal de ratón B-E8
elsilimomab
elsilimomab
elvucitabinum elvucitabine elvucitabine elvucitabina
4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydro2-furyl]pyrimidin-2(1H)-one 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxyméthyl)-2,5-dihydrofuran2-yl]pyrimidin-2(1H)-one 4-amino-5-fluoro-1-[(2S,5R)-5-(hidroximetil)-2,5-dihidro2-furil]pirimidin-2(1H)-ona C9H10FN3O3 NH 2 N O O HO H N H F
epitumomabum cituxetanum epitumomab cituxetan
Conjugate of 4-{(2RS)-2-[bis(carboxymethyl)amino]-3-({2[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)propyl}phen yl isothiocyanate forming a thiourea with the 6-amino of a lysine of immunoglobulin G1, anti-(human episialin) (mouse monoclonal HMFG-1 γ 1-chain), disulfide with mouse monoclonal HMFG-1 light chain, dimer dérivé de la thiourée produite par réaction de l'isothiocyanate de 4-[(2RS)-2-[bis(carboxyméthyl)amino]-3-[[2-[bis(carboxyméthyl)= amino]éthyl](carboxyméthyl)amino]propyl]phényle avec le 6-amino d'une lysine de l'immunoglobuline G1, anti-(human episialin) ; dimère du disulfure entre la chaîne γ 1 et la chaîne légère de l'anticorps monoclonal de souris HMFG-1 derivado de la tiourea producido por reacción del isotiocianato de 4-[(2RS)-2-[bis(carboximetil)amino]-3-[[2[bis(carboximetil)amino]etil](carboximetil)amino]propil]fenil con el 6-amino de una lisina de la inmunoglobulina G1, anti-(episialina humana) ; dímero del disulfuro entre la cadena γ 1 y la cadena ligera del anticuerpo monoclonal de ratón HMFG-1
épitumomab cituxétan
epitumomab cituxetán
93
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
HO2C HO 2C S Ig N H N H N * H N CO 2H N
CO2H CO2H and epimer at C* et l'épimère en C* y el epímero al C*
epitumomab = Ig-NH2
eptoterminum alfa eptotermin alfa eptotermine alfa eptotermina alfa
human recombinant bone morphogenetic protein 7 (hrBMP-7) or osteogenic protein-1 (OP-1) protéine-7 humaine recombinante morphogénique de l'os (PMOrh7) ou protéine-1 osteogénique (PO-1) proteína-7 humana recombinante morfogénicas de hueso (PMOrh7) o proteína-1 osteogénica (PO-1) [C683H1061N197O208S10]2 H N HN N H
exatecanum alideximerum exatecan alideximer
exatecan linked via the tetrapeptide (glycylglycylL-phenylalanylglycyl) to poly[oxy(2-hydroxymethylethylene)oxy= (hydroxymethylmethylene)] partly O -substituted with carboxymethyl groups with some carboxy groups amide linked to the tetrapeptide. exatécan lié par une chaîne tétrapeptidique (glycylglycylL-phénylalanylglycyl) à des éthers carboxyméthyliques de poly[oxy(2-hydroxyéthylidène)oxy[1-(hydroxyméthyl)éthylène]] exatecán ligado por una cadena tetrapeptídica (glicilglicilL-fenilalanilglicil) a éteres carboximetílicos de poli[oxi(2-hidroxietilideno)oxi[1-(hidroximetil)etileno]]
exatécan alideximer
exatecán alidexímero
O
O R n
=
O R CH2
O R
-H -CH2-CO2H or / ou / or : O
Gly Gly Phe Gly NH O
H N O O CH3
H3C F
N
HO
94
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
exenatidum exenatide
L-histidylglycyl- L-glutamylglycyl-L-threonyl - L-phenylalanyl- L-threonylL-seryl - L-aspartyl- L-leucyl- L-seryl- L-lysyl- L-glutaminyl- L-methionylL-glutamyl- L-glutamyl- L-glutamyl- L-alanyl- L-valyl- L-arginyl - L-leucylL-phenylalanyl- L-isoleucyl- L-glutamyl- L-tryptophyl- L-leucyl- L-lysylL-asparaginylglycylglycyl- L-prolyl- L-seryl- L-serylglycyl- L-alanylL-prolyl - L-prolyl- L-prolyl- L-serinamide
exénatide exenatida
exendine 4 (Heloderma suspectum), synthétique L-histidilglicil- L-glutamilglicil- L-treonil- L-fenilalanil- L-treonil- L-serilL-aspartil- L-leucil- L-seril- L-lisil- L-glutaminil- L-metionil- L-glutamilL-glutamil- L-glutamil- L-alanil- L-valil- L-arginil- L-leucil- L-fenilalanilL-isoleucil- L-glutamil- L-triptofil- L-leucil- L-lisil- L-asparaginilglicilglicilL-prolil- L-seril- L-serilglicil- L-alanil- L-prolil- L-prolil- L-prolil- L-serinamida
C184H282N50O60S H His Gly Glu Gly Th r Phe Th r Ser Asp Leu Ser Lys G ln Met 10
Glu Glu Gl u Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
Gly G ly Pro Ser Ser Gly 30
Ala Pro Pro Pr o Ser NH 2 39
firocoxibum firocoxib firocoxib firocoxib
3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)= phenyl]furan-2(5H)-one 3-(cyclopropylméthoxy)-5,5-diméthyl-4-[4-(méthylsulfonyl)= phényl]furan-2(5H)-one 3-(ciclopropilmetoxi)-5,5-dimetil-4-[4-(metilsulfonil)fenil]furan-2(5 H)ona C17H20O5S O O S O O O CH3 CH3 CH3
fispemifenum fispemifene fispémifène fispemifeno
2-(2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy}= ethoxy)ethanol 2-[2-[4-[(1Z)-4-chloro-1,2-diphénylbut-1-ényl]phénoxy]= éthoxy]éthanol 2-(2-{4-[(1Z)-4-cloro-1,2-difenilbut-1-enil]fenoxi}etoxi)etanol
95
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
C26H27ClO3
O
O
OH
Cl
fluoresceinum lisicolum fluorescein lisicol
N6-({3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-xanthen]5-yl}thiocarbamoyl)- N2-(3α,7α,12α-trihydroxy-5β-cholan-24-oyl)L-lysine acide (2S)-6-[[(3',6'-dihydroxy-3-oxospiro[isobenzofurane1(3H),9'-[9H]xanthén]-5-yl)thiocarbamoyl]amino]-2-[(3α,7α,12αtrihydroxy-5β-cholan-24-oyl)amino]pentanoïque ácido 5-[({(5S)-5-carboxi-5-[(3α,7α,12α-trihidroxi-5β -colan24-oil)amino]pentil}tiocarbamoil)amino]-2-(6-hidroxi-3-oxo3H-xanten-9-il)benzoico C51H63N3O11S S O H 3C CH3 H CH3 HO H H H H HO H H OH O OH O H HN H N H CO2H O NH
fluorescéine lisicol
fluoresceina lisicol
HO
H
freselestatum freselestat frésélestat
2-[5-amino-6-oxo-2-phenylpyrimidin-1(6H)-yl]- N-[(1RS)-1-(5- tertbutyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide 2-(5-amino-6-oxo-2-phénylpyrimidin-1(6H)-yl)-N-[(1RS)-1-[[5-(1,1diméthyléthyl)-1,3,4-oxadiazol-2-yl]carbonyl]-2-méthylpropyl]= acétamide 2-[5-amino-6-oxo-2-fenilpirimidin-1(6H)-il]- N-[(1RS)-1-(5- terc- butil1,3,4-oxadiazol-2-il)-3-metil-1-oxobutan-2-il]acetamida
freselestat
96
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
C23H28N6O4
H3C H3C
CH 3 O N N
O
H N O CH3 O
H H 3C
N
and enantiomer et énanti omère N y enantiómero
NH 2
galiximabum galiximab
immunoglobulin G1, anti-(human CD80 (antigen)) (human- Macaca irus monoclonal IDEC-114 heavy chain), disulfide with humanMacaca irus monoclonal IDEC-114 λ chain, dimer immunoglobuline G1, anti-(antigène CD80 humain), dimère du disulfure entre la chaîne λ et la chaîne lourde de l’anticorps monoclonal chimérique homme- macaque (Macaca irus) IDEC-114 inmunoglobulina G1, anti-(antígeno CD80 humano), dímero del disulfuro entre la cadena λ y la cadena pesada del anticuerpo monoclonal quimérico hombre-macaco ( Macaca irus ) IDEC-114
galiximab
galiximab
hemoglobinum raffimerum hemoglobin raffimer
The polyaldehyde [(2R,4S,6R,8R,11S,13R)-1,14-dihydroxy4-hydroxymethyl-3,5,7,10,12-pentaoxatetradecane-2,4,6,8,11,13hexacarbaldehyde] derived from raffinose [β -D -fructofuranosyl α- D-galactopyranosyl-(1→6)- α-D -glucopyranoside] by treatment with sodium periodate is reacted with human hemoglobin A 0 at the 2,3-DPG binding pocket. Both intermolecular and intramolecular crosslinking occurs. This product is reduced to generate covalent amine bonds with >95% crosslinked hemoglobin of which about 55% is polymerised. hémoglobine stabilisée et partiellement polymérisée, obtenue par réduction du produit de la réaction du (2R,4S,6R,8R,11S,13R)1,14-dihydroxy-4-(hydroxyméthyl)-3,5,7,10,12pentaoxatétradécane-2,4,6,8,11,13-hexacarbaldéhyde (obtenu par oxydation periodique du rafinose) avec l'hémoglobine humaine hemoglobina estabilizada y parcialmente polimerizada, obtenida por reducción del producto de la reacción del (2R,4S,6R,8R,11S,13R)1,14-dihidroxi-4-(hidroximetil)-3,5,7,10,12-pentaoxatetradecano2,4,6,8,11,13-hexacarbaldehído (obtenido por oxidación periodica de la rafinosa) con la hemoglobina humana
hémoglobine raffimer
hemoglobina rafímero
Val (βHb) HO O O HN O O OH 82
1
OH
HO
O
N
Lys (βHb)
82
N Lys (β'Hb)
97
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
icofungipenum icofungipen icofungipen icofungipeno
(1R,2S)-2-amino-4-methylenecyclopentane-1-carboxylic acid (-)-acide (1R,2S)-2-amino-4-méthylènecyclopentanecarboxylique (-)-ácido (1R,2S)-2-amino-4-metilenociclopentanocarboxílico C7H11NO2 CH2
H2N
CO 2H H H
icrocaptidum icrocaptide icrocaptide icrocaptida
glycyl- N2-ethyl- L-lysyl- L-prolyl- L-arginine glycyl-(N2-éthyl- L-lysyl)- L-prolyl-L-arginine glicil-( N2-etil- L-lisil)- L-prolil- L-arginina C21H40N8O5 H3C H2N O N H N NH2 NH2 O N H N H CO2H H NH2
O
iferanserinum iferanserin iféransérine iferanserina
( E)-2'- {2-[(2S)-1-methyl-2-piperidyl]ethyl}cinnamanilide (-)-(2E)- N-[2-[2-[(2S)-1-méthylpipéridin-2-yl]éthyl]phényl]3-phénylprop-2-énamide (-)-(2E)- N-(2-{2-[(2S)-1-metilpiperidin-2-il]etil}fenil)-3-fenilprop2-enamida C23H28N2O O NH H N CH3
98
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
istradefyllinum istradefylline istradéfylline istradefilina
8-[(E)-2-(3,4-dimethoxyphenyl)vinyl]-1,3-diethyl-7-methyl3,7-dihydro-1H-purin-2,6-dione 8-[(E)-2-(3,4-diméthoxyphényl)éthényl]-1,3-diéthyl-7-méthyl3,7-dihydro-1H-purin-2,6-dione 8-[(E)-2-(3,4-dimetoxifenil)vinil]-1,3-dietil-7-metil-3,7-dihidro1H-purin-2,6-diona C20H24N4O4 O H3C O N N CH3 N N CH3 OCH3 OCH3
ixabepilonum ixabepilone
(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16pentamethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16pentaméthyl-3-[(1E)-1-méthyl-2-(2-méthylthiazol-4-yl)éthényl]17-oxa-4-azabicyclo[14.1.0]heptadécane-5,9-dione (1S,3S,7S,10R,11S,12S,16R)-7,11-dihidroxi-8,8,10,12,16pentametil-3-[(1E)-1-(2-metil-1,3-tiazol-4-il)prop-1-en-2-il]-17-oxa4-azabiciclo[14.1.0]heptadecano-5,9-diona C27H42N2O5S H3C H H O H CH3 H NH O S N CH3
ixabépilone
ixabepilona
HO H H3C
CH3 H3C CH3 O H OH
ladostigilum ladostigil ladostigil ladostigilo
(3R)-3-(prop-2-ynylamino)indan-5-yl ethyl(methyl)carbamate éthylméthylcarbamate de (3R)-3-(prop-2-ynylamino)-2,3-dihydro1H-indén-5-yle etilmetilcarbamato de (3R)-3-(prop-2-inilamino)indan-5-ilo C16H20N2O2 O H3C N CH 3 O H
N H CH
99
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
lapatinibum lapatinib lapatinib lapatinib
N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methylsulfonyl)= ethyl]amino}methyl)-2-furyl]quinazolin-4-amine N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2(methylsulfonyl)ethyl]amino]methyl]-2-furyl]quinazolin-4-amine N-[3-cloro-4-(3-fluorobenciloxi)fenil]-6-[5-({[2-(metilsulfonil)= etil]amino}metil)-2-furil]quinazolin-4-amina C29H26ClFN4O4S N O O H3C O S O F NH HN N Cl
lomeguatribum lomeguatrib lomeguatrib lomeguatrib
6-(4-bromothenyloxy)-7H-purin-2-amine 6-[(4-bromothiophen-2-yl)methoxy]-7H-purin-2-amine 6-(4-bromoteniloxi)-7H-purin-2-amina C10H8BrN5OS S N Br H2N N N O H N
odiparcilum odiparcil odiparcil odiparcilo
4-methyl-7-(5-thio-β-D -xylopyranosyloxy)-2H-chromen-2-one 4-méthyl-7-[(5-thio-β-D -xylopyranosyl)oxy]- 2H-1-benzopyran-2-one 4-metil-7-(5-tio-β- D-xilopiranosiloxi)-2H-cromen-2-ona C15H16O6S S O OH HO OH CH3 O O
100
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
omigananum omiganan omiganan omiganán
L-isoleucyl- L-leucyl- L-arginyl - L-tryptophyl-L-prolyl- L-tryptophylL-tryptophyl- L-prolyl-L-tryptophyl- L-arginyl- L-arginyl-L-lysinamide L-isoleucyl- L-leucyl- L-arginyl - L-tryptophyl-L-prolyl- L-tryptophylL-tryptophyl- L-prolyl-L-tryptophyl- L-arginyl- L-arginyl-L-lysinamide L-isoleucil- L-leucil- L-arginil- L-triptofil- L-prolil- L-triptofil- L-triptofilL-prolil- L-triptofil- L-arginil- L-arginil- L-lisinamida
C90H127N27O12 H Ile Leu Arg Trp Pro Trp Tr p Pro Trp Arg 10
Arg
Lys NH 2
pactimibum pactimibe pactimibe pactimiba
[7-(2,2-dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid acide [7-[(2,2-diméthylpropanoyl)amino]-4,6-diméthyl-1-octyl2,3-dihydro-1H-indol-5-yl]acétique ácido [7-(2,2-dimetilpropanamido)-4,6-dimetil-1-octilindolin-5-il] acético C25H40N2O3 CH3 CO2H N HN CH3 O CH3 CH3
H3C
H 3C
patupilonum patupilone
(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16pentamethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16pentaméthyl-3-[(1E)-1-méthyl-2-(2-méthylthiazol-4-yl)éthényl]4,17-dioxabicyclo[14.1.0]heptadécane-5,9-dione (1S,3S,7S,10R,11S,12S,16R)-7,11-dihidroxi-8,8,10,12,16pentametil-3-[(1E)-1-(2-metil-1,3-tiazol-4-il)prop-1-en-2-il]4,17-dioxabiciclo[14.1.0]heptadecano-5,9-diona C27H41NO6S H3C H H O H CH3 H O O S CH3 N
patupilone
patupilona
HO H H3C
CH3 H3C CH3 O H OH
101
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
pertuzumabum pertuzumab
immunoglobulin G1, anti-(human ν (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 κ-chain, dimer immunoglobuline G1, anti-(récepteur ν humain), dimère du disulfure entre la chaîne κ et la chaîne lourde de l’anticorps monoclonal de souris humanisé 2C4 inmunoglobulina G1, anti-(receptor ν humano), dímero del disulfuro entre la cadena κ y la cadena pesada del anticuerpo monoclonal humanizado de ratón 2C4
pertuzumab
pertuzumab
pixantronum pixantrone pixantrone pixantrona
6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione 6,9-bis[(2-aminoéthyl)amino]benzo[g]isoquinoléine-5,10-dione 6,9-bis[(2-aminoetil)amino]benzo[g]isoquinolina-5,10-diona C17H19N5O2 O HN NH2
N O HN
NH2
pritumumabum pritumumab
immunoglobulin G, anti-(human vimentin) (human monoclonal CLN G11 γ 1-chain), disulfide with human monoclonal CLN G11 κ-chain, dimer immunoglobuline G, anti-(vimentine humaine) ; dimère du disulfure entre la chaîne γ 1 et la chaîne κ de l'anticorps monoclonal humain CLN H11 inmunoglobulina G, anti-(vimentina humana); dímero del disulfuro entre la cadena γ 1 y la cadena κ del anticuerpo monoclonal humano CLN H11 C6440H9968N1708O2016S42
pritumumab
pritumumab
ralfinamidum ralfinamide ralfinamide ralfinamida
(2S)-2-[4-(2-fluorobenzyloxy)benzylamino]propanamide (+)-(2S)-2-[[4-[(2-fluorobenzyl)oxy]benzyl]amino]propanamide (+)-(2S)-2-[4-(2-fluorobenciloxi)bencilamino]propanamide
102
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
C17H19FN2O2 H CH3 N H O F NH2 O
rebimastatum rebimastat rébimastat
N-[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin1-yl)butanoyl]-L-leucyl- N1,3-dimethyl- L-valinamide (2S)-N-[(1S)-2,2-diméthyl-1-(méthylcarbamoyl)propyl]-4-méthyl2-[[(2S)-2-sulfanyl-4-(3,4,4-triméthyl-2,5-dioxoimidazolidin1-yl)butanoyl]amino]pentanamide N-[(2S) -2-sulfanil-4-(3,4,4-trimetil-2,5-dioxoimidazolidin1-il)butanoil]- L-leucil-N1,3-dimetil- L-valinamida C23H41N5O5S CH 3 CH3 O H3C O H N H SH H H N O H 3C O N H H CH 3 CH 3 CH 3
rebimastat
H 3C H3C N
N O
segesteronum segesterone ségestérone segesterona
17-hydroxy-16-methylene-19-norpregn-4-ene-3,20-dione 17-hydroxy-16-méthylène-19-norprégn-4-ène-3,20-dione 17-hidroxi-16-metileno-19-norpregn-4-eno-3,20-diona C21H28O3 O CH3 H H O H H CH3 OH CH2
semapimodum semapimod sémapimod semapimod
N,N'-bis{3,5-bis[1-(carbamimidoylhydrazono)ethyl]phenyl}= decanediamide N,N'-bis[3,5-bis[N-(carbamimidoylamino)acétimidoyl]phényl]= décanediamide N,N'-bis{3,5-bis[1-(carbamimidoilhidrazono)etil]fenil}= decanodiamida
103
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
C34H52N18O2 H N NH NH O CH 3 N CH3 N H N NH
H2 N O HN NH H2 N N H N CH3 N CH3 N H NH
NH 2
NH2
sufugolixum sufugolix
5-{[benzyl(methyl)amino]methyl}-1-(2,6-difluorobenzyl)-6-[4(3-methoxyureido)phenyl]-3-phenylthieno[2,3- d]pyrimidine2,4(1H,3H)-dione 1-[4-[5-[(benzylméthylamino)méthyl]-1-(2,6-difluorobenzyl)2,4-dioxo-3-phényl-1,2,3,4-tétrahydrothiéno[2,3- d]pyrimidin6-yl]phényl]-3-méthoxyurée 5-{[bencil(metil)amino]metil}-1-(2,6-difluorobencil)-6-[4(3-metoxiureido)fenil]-3-feniltieno[2,3- d]pirimidina-2,4(1H,3H)-diona C36H31F2N5O4S F
sufugolix
sufugolix
H3C
O HN
O HN
F S
N N O
O
N H3C
tacapenemum tacapenem
(+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(3R)-5oxopyrrolidin-3-yl]sulfanyl]-1-azabicyclo[3.2.0]hept-2-ene2-carboxylic acid (+)-acide (4R,5S,6S)-6-[(1R)-1-hydroxyéthyl]-4-méthyl-7-oxo3-[[(3R)-5-oxopyrrolidin-3-yl]sulfanyl]-1-azabicyclo[3.2.0]hept-2-ène2-carboxylique (+)-ácido (4R,5S,6S)-6-[(1R)-1-hidroxietil]-4-metil-7-oxo-3-[[(3R)-5oxopirrolidin-3-il]sulfanil]-1-azabiciclo[3.2.0]hept-2-eno-2-carboxílico
tacapénem
tacapenem
104
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
C14 H1 8N2O5 S O H3C HO N CO 2H
S H H H H H CH3
O N H
tafluprostum tafluprost tafluprost tafluprost
isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut1-enyl]-3,5-dihydroxycyclopentyl}hept-5-enoate (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phénoxybut-1-ényl]3,5-dihydroxycyclopentyl]hept-5-énoate de 1-méthyléthyle (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-fenoxibut-1-enil]3,5-dihidroxiciclopentil}hept-5-enoato de isopropilo C25H34F2O5 H OH H
O O
CH3 CH3
HO
H
H
O F F
talizumabum talizumab
immunoglobulin G, anti-(human immunoglobulin E Fc region) (human-mouse monoclonal Hu901 γ -chain), disulfide with humanmouse monoclonal Hu901 κ-chain, dimer immunoglobuline G, anti-(région Fc de l’immunoglobuline E humaine), dimère du disulfure entre la chaîne κ et la chaîne γ de l’anticorps monoclonal de souris humanisé Hu901 inmunoglobulina G, anti-(región Fc de la inmunoglobulina E humana), dímero del disulfuro entre la cadena κ y la cadena γ del anticuerpo monoclonal humanizado de ratón Hu901
talizumab
talizumab
technetium (99mTc) nitridocadum technetium (99mTc) nitridocade technétium (99mTc) nitridocade
( SPY-5-21)-bis[ethoxy(ethyl)dithiocarbamato- κS,κS']nitrido= [99mTc]technetium ( SPY-5-21)-bis(éthoxyéthyldithiocarbamato- κS,κS')nitrido= [99mTc]technétium ( SPY-5-21)-bis(etoxietilditiocarbamato- κS,κS')nitrido[99m Tc]tecnecio
tecnecio (99mTc) nitridocado
105
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
C10H20N3O2S499mTc H3C O N H3C S S N 99m
S N S
CH3 O CH3
Tc
tesofensinum tesofensine tésofensine tesofensina
(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl8-azabicyclo[3.2.1]octane (1R,2R,3S,5S)-3-(3,4-dichlorophényl)-2-(éthoxyméthyl)-8-méthyl8-azabicyclo[3.2.1]octane (1R,2R,3S,5S)-3-(3,4-diclorofenil)-2-(etoximetil)-8-metil8-azabiciclo[3.2.1]octano C17H23Cl2 NO H H H Cl Cl CH3 O N CH3 H
tifenazoxidum tifenazoxide
6-chloro- N-(1-methylcyclopropyl)-1,1-dioxo-1,4-dihydro-1λ6thieno[3,2- e][1,2,4]thiadiazin-3-amine 1,1-dioxyde de 6-chloro- N-(1-méthylcyclopropyl)-4H-thiéno[3,2- e]1,2,4-thiadiazin-3-amine 1,1-dióxido de 6-cloro- N-(1-metilciclopropil)-4H-tieno[3,2- e]-1,2,4tiadiazin-3-amina C9H10ClN3O2S2 O O S N N H N H CH3
tifénazoxide tifenazóxido
S Cl
tisocalcitatum tisocalcitate tisocalcitate tisocalcitato
isopropyl (1S,3R,5Z,7E,22E,24R)-1,3,24-trihydroxy9,10-secocholesta-5,7,10(19),22-tetraene-25-carboxylate (5Z,7E,22E,24R)-1α,3β ,24-trihydroxy-9,10-sécocholesta5,7,10(19),22-tétraène-25-carboxylate de 1-méthyléthyle (1S,3R,5Z,7E,22E,24R)-1,3,24-trihidroxi-9,10-secocolesta5,7,10(19),22-tetraeno-25-carboxilato de isopropilo
106
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
C31H48O5 H3C H CH3 H H3C H CH2 HO H H OH CH3 O H OH
O
CH3 CH3
ulifloxacinum ulifloxacin ulifloxacin ulifloxacino
(1RS)-6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)4H-[1,3]thiazeto[3,2- a]quinoline-3-carboxylic acid acide (1RS)-6-fluoro-1-méthyl-4-oxo-7-(pipérazin-1-yl)4H-[1,3]thiazéto[3,2- a]quinoléine-3-carboxylique ácido (1RS)-6-fluoro-1-metil-4-oxo-7-(piperazin-1-il)4H-[1,3]tiazeto[3,2- a]quinolina-3-carboxílico C16H16FN3O3S H CH3 HN N N S and enantiomer et énantiomère y enantiómero
F O
CO 2H
vareniclinum varenicline varénicline vareniclina
7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (6R,10S)-7,8,9,10-tétrahydro-6,10-méthano-6H-pyrazino[2,3h][3]benzazépine 7,8,9,10-tetrahidro-6H-6,10-metanoazepino[4,5- g]quinoxalina C13H13N3 H N HN N H
107
Recommended INN: List 51
WHO Drug Information, Vol. 18, No. 1, 2004
AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES Recommended International Nonproprietary Names (Rec. INN): List 04 Dénominations communes internationales recommandées (DCI Rec.): Liste 04 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 04 (Crónica de la OMS, Vol. 16, N° 4, Abril de 1962) p. 158 suprimase metodilazina insértese metdilazina
Recommended International Nonproprietary Names (Rec. INN): List 06 Dénominations communes internationales recommandées (DCI Rec.): Liste 06 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 06 (WHO Chronicle, Vol. 20, No. 11, 1967) (Chronique OMS, Vol. 20, N° 11, 1967) (Crónica de la OMS, Vol. 21, N° 11, 1967) lauromacrogolum 400 lauromacrogol 400
p. 427
replace the description by the following: polyethylene glycol monododecyl ether, the name is followed by a number (400) corresponding approximately to the average molecular mass of the polyethylene glycol portion remplacer la description par la suivante: α-dodécyl-ω-hydroxypoly(oxyéthylène), la masse moyenne de la partie macrogol (# 44n+18) est indiquée entre parenthèses après la dénomination sustitúyase la descripción por la siguiente: éter monododecílico del polietilen glicol, al nombre le sigue un número (400) que corresponde aproximadamente a la masa molecular media de la fracción polietilenglicol
p. 474
lauromacrogol 400
p. 340
lauromacrogol 400
Recommended International Nonproprietary Names (Rec. INN): Lis t 40 Dénominations communes internationales recommandées (DCI Rec.): Liste 40 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 40 (WHO Drug Information, Vol. 12, No. 3, 1998) p. 194 supprimer pregabaline insérer prégabaline
108
WHO Drug Information, Vol. 18, No. 1, 2004
Recommended INN: List 51
Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in uneven numbers of proposed INN lists only. Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques seront publiés seulement dans les numéros impairs des listes des DCIs proposées. El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.
109